Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (521-530 of 869) with videos related to

Pageof 87
Sort By:
Haematologica|September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaMeletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Future Oncology (London, England)|January 24, 2025
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myelomaPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Cancer Research|April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.
Blood Advances|July 26, 2022
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15Rafael Alonso Fernandez, Jessica Encinas Mayoral, Laetitia Pierre-Louis, et al.
British Journal of Haematology|September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Cancer Research|October 3, 2003
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsSteven P Treon, Linda M Pilarski, Andrew R Belch, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Pageof 87

Showing results (521-530 of 869) with videos related to

Sort By:
Pageof 87
Haematologica|September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaMeletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Future Oncology (London, England)|January 24, 2025
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myelomaPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Cancer Research|April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.
Blood Advances|July 26, 2022
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15Rafael Alonso Fernandez, Jessica Encinas Mayoral, Laetitia Pierre-Louis, et al.
British Journal of Haematology|September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Cancer Research|October 3, 2003
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsSteven P Treon, Linda M Pilarski, Andrew R Belch, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Pageof 87